[Case of obstructive jaundice as initial manifestation of non Hodgkin lymphoma in patient followed as chronic hepatitis C].
Hidaka
Satoshi
S
Center for Liver and Billiary Diseases, Matsuyama Red Cross Hospital.
Takechi
Shunji
S
Nonaka
Suguru
S
Joko
Kouji
K
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D003520:Cyclophosphamide / Q000008:administration & dosage; D003952:Diagnostic Imaging; D004317:Doxorubicin / Q000008:administration & dosage; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D041781:Jaundice, Obstructive / Q000209:etiology*; D008228:Lymphoma, Non-Hodgkin / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D011239:Prednisolone / Q000008:administration & dosage; D015375:Receptors, Interleukin-2 / Q000097:blood; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D014408:Biomarkers, Tumor; D015375:Receptors, Interleukin-2; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone